HOXA9 和 CD163 增强胰腺导管腺癌的进展。

HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression.

机构信息

Pathology Department, Faculty of Medicine, Menoufia University, Yassin Abd Elghafar Street, Shibin El Kom, Menoufia, 32511, Egypt.

Pathology Technician Fellow, National Liver Institute- Menoufia University, Shibin El Kom, Egypt.

出版信息

Diagn Pathol. 2024 Oct 26;19(1):141. doi: 10.1186/s13000-024-01563-5.

DOI:10.1186/s13000-024-01563-5

PMID:39462379

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11514874/

Abstract

BACKGROUND

The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevance of HOXA9 and CD163 in PDAC progression.

MATERIALS AND METHODS

Selected 98 PDAC and 98 adjacent non tumor tissues as a control group were immunostained with HOXA9 and CD163 antibodies.

RESULTS

PDAC displayed highly significant higher HOXA9 staining intensity, percent and H score values than control group. HOXA9 staining of PDAC cases showed significant associations with poor prognostic indicators including larger tumor size, higher grade and advanced stage. PDAC showed highly significant differences regarding CD163 macrophage-specific staining intensity, percent and H score values than control group. CD163 showed significant higher expressions with larger tumor size, higher histological grade and advanced stage group. HOXA9 staining in PDAC showed highly significant direct correlations with CD163 positive macrophages. Follow up of PDAC cases revealed that high median H score of HOXA9 and CD163 were significantly associated with worse overall survival. CD163 was an independent prognostic marker of worse survival.

CONCLUSIONS

In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.

摘要

背景

HOXA9 的作用需要在胰腺导管腺癌 (PDAC) 中进行研究，因为正在开发 HOXA9 抑制剂。HOXA9 可能会吸引表达 CD163 的肿瘤相关巨噬细胞 (TAM)，并可能影响 PDAC 的预后。这项工作旨在研究 HOXA9 和 CD163 在 PDAC 进展中的表达和相关性。

材料和方法

选择 98 例 PDAC 和 98 例相邻非肿瘤组织作为对照组，用 HOXA9 和 CD163 抗体进行免疫染色。

结果

PDAC 的 HOXA9 染色强度、百分比和 H 评分值明显高于对照组。PDAC 的 HOXA9 染色与包括肿瘤较大、分级较高和分期较晚在内的不良预后指标有显著相关性。PDAC 的 CD163 巨噬细胞特异性染色强度、百分比和 H 评分值明显高于对照组。CD163 的表达与肿瘤较大、组织学分级较高和分期较晚的组显著相关。PDAC 中的 HOXA9 染色与 CD163 阳性巨噬细胞有显著的直接相关性。对 PDAC 病例的随访显示，HOXA9 和 CD163 的中位 H 评分较高与总体生存率较差显著相关。CD163 是预后较差的独立预后标志物。